Cardiotoxicity associated with Herceptin (trastuzumab) therapy: A potential mechanism

被引:0
|
作者
Zuppinger, C
Sawyer, DB
Miller, T
Eppenberger, HM
Suter, TM
机构
[1] Univ Hosp Bern, CH-3010 Bern, Switzerland
[2] Boston Univ, Dept Med, Myocardial Biol Unit, Boston, MA 02215 USA
[3] Fed Inst Technol ETH, Inst Cell Biol, Zurich, Switzerland
关键词
D O I
10.1016/S0959-8049(02)80300-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
214
引用
收藏
页码:S96 / S96
页数:1
相关论文
共 50 条
  • [31] Exploring the potential molecular mechanism of trastuzumab-induced cardiotoxicity based on RNA sequencing and bioinformatics analysis
    Hou, Huan
    Xu, Ying
    Xie, Meilin
    Chen, Rong
    BIOCHEMICAL PHARMACOLOGY, 2023, 208
  • [33] Docetaxel (Taxotere®) combined with trastuzumab (Herceptin)
    Ficorella, C
    TUMORI JOURNAL, 2001, 87 (01): : S10 - S18
  • [34] The development and clinical use of trastuzumab (Herceptin)
    Harries, M
    Smith, I
    ENDOCRINE-RELATED CANCER, 2002, 9 (02) : 75 - 85
  • [35] Trastuzamab (Herceptin®)-related cardiotoxicity in pregnancy
    Roberts, Nicole J.
    Auld, Barry J.
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2010, 103 (04) : 157 - 159
  • [37] Herceptin (trastuzumab): Adjuvant and neoadjuvant trials
    Yaal-Hahoshen, Neora
    Safra, Tamar
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2006, 8 (06): : 416 - 421
  • [38] Herceptin® (Trastuzumab) and the Incidence of Spontaneous Abortion
    Daniels, S.
    Johnston, M.
    Hiles, L.
    DRUG SAFETY, 2011, 34 (10) : 987 - 988
  • [39] Herceptin® (Trastuzumab): Risk Management Planning
    Daniels, S.
    Johnston, M.
    Hiles, L.
    DRUG SAFETY, 2011, 34 (10) : 905 - 905
  • [40] Bleeding risk with trastuzumab (Herceptin) treatment
    Nissenblatt, MJ
    Karp, GI
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (24): : 2299 - 2300